Case Study Initial Presentation Case Study Medical History Case Study Physical Examination Case Study Test Results Determinants of Prognosis in PAH Risk Assessment in PAH From the 2015 ESCERS Guidelines ID: 701379
Download Presentation The PPT/PDF document "Goal-Directed Treatment of PAH" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Goal-Directed Treatment of PAHSlide2
Case Study
Initial PresentationSlide3
Case StudyMedical HistorySlide4
Case Study
Physical ExaminationSlide5
Case Study
Test Results Slide6
Determinants of Prognosis in PAHSlide7
Risk Assessment in PAH
From the 2015 ESC/ERS GuidelinesSlide8
Algorithm for Treatment-Naive PAH PatientSlide9
Monotherapy Recommendations for PAHSlide10
Sequential Combination Therapy Recommendations for WHO FC III PAHSlide11
Key Pathways Involved in Pathogenesis of PAHSlide12
The Rationale for Combination TherapySlide13
An Evolving Paradigm
From Sequential to Initial Up-front Combination TherapySlide14
Recommendations for Initial
Combination TherapySlide15
Initial Use of Ambrisentan + Tadalafil in PAH
The AMBITION Trial Slide16
AMBITION Study
Primary Endpoint ResultsSlide17
3 European Registry ReportsSlide18
French RegistrySlide19
French Registry (cont)Slide20
French Registry: Survival Based on Number of Low-Risk Criteria Achieved at First EvaluationSlide21
French Registry
BNP Subset AnalysisSlide22
COMPERA RegistrySlide23
SWEDISH Registry (SPAHR)Slide24
Case Study
Patient Initiates PAH TreatmentSlide25
Case Study
Follow-Up 2 Months Later Slide26
Treatment Approaches to Clinical FailureSlide27
Therapies Targeting the Prostacyclin PathwaySlide28
GRIPHON
Study DesignSlide29
Effect of Selexipag on Primary Composite Endpoint in GRIPHON Slide30
GRIPHON
Treatment Effect by SubgroupSlide31
Case Study:Worrisome Features of This CaseSlide32
Take-Home PointsSlide33